Skip to main content

Table 3 Percentage of IBD patients with at least one of the listed medical claims (n = 13,451)

From: Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014

% Total 2010 2012 2014
5-ASAa 87.4 96.8 84.8 82.2
Immunosuppressantsb 23.2 18.7 24.4 25.9
Biologicsc 9.7 5.3 10.2 12.8
Steroidsd 35.0 32.8 36.5 35.3
  1. amesalazine, sulfasalazine
  2. bmethotrexate, azathioprine, mercaptopurine
  3. cinfliximab, adalimumab, golimumab, certolizumab pegol
  4. dprednisone, prednisolone, methylprednisolone, budesonide